Results 171 to 180 of about 95,316 (246)
Ubiquitination and degradation of CD47 enhances macrophage phagocytosis of hemolytic erythrocytes. [PDF]
Wang Y +10 more
europepmc +1 more source
ABSTRACT Postpartum hemorrhage (PPH) remains the leading cause of preventable maternal mortality despite standard interventions. Recent fibrinogen trials failed to improve outcomes, prompting interest in coagulation factor XIII (FXIII). FXIII functions as “molecular cement,” cross‐linking fibrin and stabilizing clots.
Jeremy W. Jacobs +8 more
wiley +1 more source
Mechanically-foldable axial flow blood pump: response-surface-based structural optimization and hemolytic performance evaluation. [PDF]
Ji T, Jing T, Cheng J.
europepmc +1 more source
ABSTRACT Acute chest syndrome (ACS) is one of the most common severe complications of sickle cell disease (SCD). In recent years, a major role of inflammation and innate immunity has been evidenced, but ACS pathophysiology remains incompletely understood, and therapeutic options are limited.
Slimane Allali +14 more
wiley +1 more source
A Rare Case of Acute Hemolysis After Rasburicase Infusion. [PDF]
Broadway-Duren JB, Gardiner TP.
europepmc +1 more source
ABSTRACT Sickle cell disease (SCD) is a chronic inflammatory state, characterized by increased plasma values of inflammatory and angiogenic proteins. Although red blood cell (RBC) transfusion is known to have immunomodulatory effects in other conditions, its potential effects on the inflammatory state in SCD remain largely unknown.
Lydian A. de Ligt +9 more
wiley +1 more source
Two Cases of Methemoglobinemia Secondary to Favism in Pediatric Patients With Unknown Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency. [PDF]
Sawaftah MA +3 more
europepmc +1 more source
Genetic Contribution to Asthma Informs Acute Chest Syndrome Pathophysiology and Risk Stratification
ABSTRACT Acute chest syndrome (ACS) is a severe complication of sickle cell disease (SCD) occurring in ~50% of patients, some presenting frequent episodes. We lack tools to identify patients at high risk of ACS occurrence or frequent episodes. Epidemiological studies have found an association between asthma and ACS, but whether this link is causal is ...
Sara El Aouhel +10 more
wiley +1 more source
ABSTRACT Ravulizumab, a second‐generation complement component 5 inhibitor (C5i) derived from eculizumab, with improved pharmacokinetics, is the current standard‐of‐care treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), where available.
Alexander Röth +8 more
wiley +1 more source

